Latest Updates
What's new on Blossom
Stay up to date with the latest research papers, clinical trials, blog posts, and site updates.
Loading updates...
Stay up to date with the latest research papers, clinical trials, blog posts, and site updates.
AtaiBeckley (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company developing psychedelic treatments for treatment-resistant depression, alcohol use disorder, and social anxiety disorder. Formed from the merger of atai Life Sciences and Beckley Psytech in 2025.
Perception Neuroscience is a New York–based biopharmaceutical subsidiary of atai Life Sciences developing PCN-101 (arketamine, R-ketamine) as a potentially safer, lower-dissociation alternative to racemic ketamine for treatment-resistant depression. The company completed a Phase 1 single-ascending-dose study in 58 healthy volunteers and a Phase 2a double-blind, placebo-controlled trial in TRD patients, with a collaboration with Otsuka Pharmaceutical for the Japanese market.
EmpathBio Inc. is an ATAI Life Sciences subsidiary developing EMP-01, an MDMA derivative designed to preserve entactogenic therapeutic properties while reducing cardiovascular and stimulant side effects, with PTSD as the primary indication. The company completed a Phase 1 trial of EMP-01 in 32 healthy volunteers in New Zealand.
DemeRx develops DMX-1001 (noribogaine), a non-psychedelic ibogaine metabolite for alcohol use disorder.
Eli Lilly and Company (NYSE: LLY) is one of the world's largest pharmaceutical companies, headquartered in Indianapolis, Indiana and founded in 1876, best known for its diabetes, obesity and neuroscience medicines. Lilly entered the psychedelic field in July 2026 by agreeing to acquire AtaiBeckley for up to approximately US$3.8 billion (US$6.75 per share in upfront cash, about US$2.8 billion, plus up to US$2.50 per share in milestone-based contingent value rights). Expected to close in the third quarter of 2026, the deal brings Lilly a late-stage psychedelic and neuroplastogen pipeline led by BPL-003, an intranasal formulation of mebufotenin (5-MeO-DMT) in Phase 3 for treatment-resistant depression, alongside VLS-01 (a DMT oral film) and EMP-01 (an oral (R)-MDMA candidate). It is the largest psychedelic-focused acquisition to date, though Lilly notably avoided the term "psychedelic" in its announcement.
Eleusis Therapeutics was a psychedelic-medicine company, founded by Shlomi Raz, that developed short-duration psychedelic therapeutics, most notably ELE-101, an intravenous formulation of psilocin (the active metabolite of psilocybin). After an attempted public listing was abandoned in early 2022, Eleusis was acquired in full by Beckley Psytech in October 2022 in an all-equity deal, with its research team integrated into Beckley and Raz becoming Beckley's chief business officer. Beckley's later combination with atai Life Sciences formed AtaiBeckley in November 2025, which Eli Lilly agreed to acquire in July 2026. However, the ELE-101 asset itself was carved out of Beckley and returned to shareholders shortly before the atai merger, so it did not pass into AtaiBeckley or the Lilly transaction.
GH Research (NASDAQ: GHRS) develops mebufotenin (5-MeO-DMT) treatments for TRD, bipolar II, and postpartum depression. GH001 Phase 2b met primary endpoint; Phase 3 initiating 2026.
This Phase II, single-group trial (n=18) will evaluate the safety and efficacy of group retreat psilocybin therapy for treating anxiety and depression in patients with metastatic solid tumours or incurable hematologic malignancies. The study aims to address the profound suffering caused by unrelieved anxiety and existential distress in this population by using psilocybin, which is believed to disrupt negative thought patterns and enhance mood regulation. Participants will receive a pharmaceutical-grade psilocybin orally, with a potential booster dose administered based on clinical judgement. Participants will engage in a series of preparatory and integration therapy sessions, both virtual and in-person, leading up to and following the psilocybin administration. The treatment regimen includes group preparation sessions on days -14, -7, and -1, an individual preparation session on day -1, and integration sessions on days 1, 8, 15, and 22. Following the treatment, patients will be monitored for adverse events over a period of up to 6 months, with follow-up assessments at 8, 12, and 24 weeks post-treatment. The study is set to begin in April 2026 and aims to provide insights into the therapeutic potential of psilocybin in this vulnerable patient group.
Healing Hearts, Changing Minds, Inc. (HHCM) is a Massachusetts-based nonprofit grant foundation committed to trust-based philanthropy in psychedelic-assisted therapy, founded by Robert Ansin following a transformative personal psilocybin experience. The foundation has awarded over $566,000 in grants under its 'Walking Each Other Home' fund to support psilocybin and ketamine-assisted therapy in end-of-life care, including funding for war-affected Ukrainian veterans.
The James J. Peters VA Medical Center (Bronx VA) in New York is home to the Center for Psychedelic Psychotherapy and Trauma Research—a joint initiative with Mount Sinai's Icahn School of Medicine led by Dr. Rachel Yehuda—which pioneered the first FDA-approved randomized MDMA-assisted psychotherapy trial within the VA system and has conducted ketamine-based trials for chronic PTSD and suicidal ideation in veterans. The center is one of nine VA facilities participating in the expanded national VA psychedelic-assisted therapy research program.
This Phase I/Phase II, non-randomised, triple‑masked, sequential trial (n=30) will evaluate the safety and tolerability of oral psilocybin (5 mg, 10 mg and 25 mg) in veterans with chronic spinal cord injury and a diagnosed depressive disorder. The primary focus is to determine whether psilocybin increases the number or severity of treatment‑related adverse events (recorded in an adverse events log) over the study period, with secondary assessment of tolerability of the psychedelic experience and effects on depression severity, pain, muscle spasms, autonomic measures and quality of life. Thirty participants (15 with paraplegia and 15 with tetraplegia) will be allocated to one of three dose cohorts (low 5 mg, medium 10 mg, high 25 mg) in a stepwise safety design; participants will be masked to dose. Enrolment covers up to 13 months and includes at least 16 study visits (including seven visits comprising psilocybin‑assisted therapy), in‑person visits at the VA medical centre and remote visits, and follow‑up assessments through study completion. Key eligibility requirements include age ≥22 years, chronic spinal cord injury ≥1 year, weight ≥50 kg, ability to swallow pills and to taper antidepressants under clinician supervision; major exclusions include recent psychedelic, ketamine or ECT exposure, Bipolar I disorder, certain substance use disorders, uncontrolled hypertension and pregnancy or nursing.
The Johns Hopkins Center for Psychedelic and Consciousness Research sits within the School of Medicine in Baltimore and is one of the most established programmes of its kind. It opened in 2019 with roughly 17 million dollars in private donations, and was founded under Roland Griffiths, whose earlier psilocybin work helped revive modern clinical study of these compounds. Frederick Barrett took over as director in 2023. The centre studies how classic psychedelics such as psilocybin affect brain function, cognition and mood, and runs trials in conditions including depression, tobacco dependence and anorexia. Its scientists combine clinical trials with neuroimaging and questionnaire measures of the psychedelic experience, and much of the field's shared vocabulary traces back to work done here.